What was the market valuation of the US morphine market in 2024?

The market valuation of the US morphine market was $3700.0 Million in 2024. Read More

What is the projected market valuation for the US morphine market by 2035?

The projected market valuation for the US morphine market is $7300.0 Million by 2035. Read More

What is the expected CAGR for the US morphine market during the forecast period 2025 - 2035?

The expected CAGR for the US morphine market during the forecast period 2025 - 2035 is 6.37%. Read More

What are the main dosage forms of morphine in the US market?

The main dosage forms of morphine in the US market include Injection, Oral, and Other Dosage Forms, with Oral valued at $2200.0 Million in 2024. Read More

How is the US morphine market segmented by application?

The US morphine market is segmented by application, with Pain Management valued at $2220.0 Million in 2024. Read More

What distribution channels are utilized in the US morphine market?

Distribution channels in the US morphine market include Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies, with Retail Pharmacies valued at $1500.0 Million in 2024. Read More

What are the end-user segments in the US morphine market?

End-user segments in the US morphine market include Hospitals & Clinics, valued at $2000.0 Million in 2024. Read More

What is the projected growth trend for the US morphine market from 2025 to 2035?

The US morphine market is expected to experience growth, reaching a valuation of $7300.0 Million by 2035. Read More

How does the US morphine market's performance in 2024 compare to its projected performance in 2035?

The US morphine market's performance in 2024, valued at $3700.0 Million, is expected to nearly double by 2035, reaching $7300.0 Million. Read More

US Morphine Market

Q: Which companies are key players in the US morphine market?

Key players in the US morphine market include Purdue Pharma, Mallinckrodt Pharmaceuticals, Teva Pharmaceutical Industries, and others. Read More

ID: MRFR/HC/14780-HCR 100 Pages Rahul Gotadki Last Updated: September 15, 2026

US Morphine Market Research Report By Dosage Form (Injection, Oral, Other Dosage Forms), By Application (Pain Management, Diarrhea Suppressant, Cold & Cough Suppressant, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others) - Growth & Industry Forecast 2025 To 2035

US Morphine Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.37%

2024 Market Size$ 3,700 Million

2025 Market Size$ 3,935.69 Million

2035 Market Size$ 7,300 Million

Key Players

Purdue Pharma

Mallinckrodt Pharmaceuticals

Teva Pharmaceutical Industries

Mundipharma

Hikma Pharmaceuticals

Sandoz

Trends

Rising Demand for Pain Management Solutions
Evolving Regulatory Landscape
Innovations in Pharmaceutical Formulations

Opportunities

Growing Awareness of Palliative Care
Advancements in Pain Management Protocols
Regulatory Support for Opioid Prescriptions

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Dosage Form (USD Million)
  1. 4.1.1 Injection
  2. 4.1.2 Oral
  3. 4.1.3 Other Dosage Forms
2. 4.2 Life Sciences, BY Application (USD Million)
  1. 4.2.1 Pain Management
  2. 4.2.2 Diarrhea Suppressant
  3. 4.2.3 Cold & Cough Suppressant
  4. 4.2.4 Others
3. 4.3 Life Sciences, BY Distribution Channel (USD Million)
  1. 4.3.1 Hospital Pharmacies
  2. 4.3.2 Retail Pharmacies
  3. 4.3.3 Online Pharmacies
  4. 4.3.4 Others
4. 4.4 Life Sciences, BY End User (USD Million)
  1. 4.4.1 Hospitals & Clinics
  2. 4.4.2 Ambulatory Surgical Centers
  3. 4.4.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Purdue Pharma (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Mallinckrodt Pharmaceuticals (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Teva Pharmaceutical Industries (IL)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Mundipharma (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Hikma Pharmaceuticals (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sandoz (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Amgen (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Boehringer Ingelheim (DE)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 AstraZeneca (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DOSAGE FORM
3. 6.3 US MARKET ANALYSIS BY APPLICATION
4. 6.4 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY DOSAGE FORM, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY DOSAGE FORM, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY APPLICATION, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY APPLICATION, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY END USER, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DOSAGE FORM, 2025-2035 (USD Million)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Morphine Market Segmentation

US Morphine Market By Dosage Form (USD Million, 2025-2035)

Injection
Oral
Other Dosage Forms

US Morphine Market By Application (USD Million, 2025-2035)

Pain Management
Diarrhea Suppressant
Cold & Cough Suppressant
Others

US Morphine Market By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

US Morphine Market By End User (USD Million, 2025-2035)

Hospitals & Clinics
Ambulatory Surgical Centers
Others

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”